What Is GLP-1? The Hormone, Receptor and Medicines Explained

GLP-1 stands for glucagon-like peptide-1, a hormone involved in the body’s response to food. It helps coordinate blood-glucose regulation and appetite. A GLP-1 receptor agonist is a medicine that activates the hormone’s receptor; it is not the same thing as the naturally occurring hormone.

That distinction explains several confusing headlines. Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts at both GIP and GLP-1 receptors. Retatrutide is studied as a three-receptor agonist. The number of targets describes a mechanism, not a ranking of clinical benefit.

Sources checked: 23 October 2026. This explainer covers terminology, biology and how to read evidence. Current Australian registration and subsidy decisions are covered in our GLP-1 Australia status guide.

GLP-1, its receptor and the medicine: three different things

“Peptide” describes molecular structure; “hormone” describes a signalling role. GLP-1 is both. Our peptide, protein and hormone classification guide explains why those categories overlap.

What does GLP-1 do in the body?

GLP-1 belongs to the incretin system linking nutrient intake with insulin secretion. Research in mouse and human pancreatic islets helps explain how GLP-1 can amplify the insulin response to glucose. Those laboratory findings describe a biological pathway; they are not a trial of long-term treatment outcomes. Shigeto and colleagues’ primary study makes that experimental setting explicit.

These effects are described in semaglutide prescribing information, sections 12.1–12.2, and the TGA’s class safety update. A pathway diagram cannot replace the evidence and warnings for a particular medicine.

How do GLP-1 medicines differ from the natural hormone?

The body’s active GLP-1 is broken down by the enzyme DPP-4. Medicines can be designed to resist breakdown or remain in circulation longer. For example, semaglutide has changes that protect it from DPP-4 degradation and support albumin binding. Its prescribing information explains those properties; they should not be assumed for every receptor agonist.

A shared receptor target also does not require a shared molecular structure. Orforglipron is a non-peptide small molecule with GLP-1 receptor activity. The FDA review record describes that classification, while the Foundayo label identifies an oral tablet formulation. “GLP-1 medicine” therefore does not mean “peptide injection”.

GLP-1, dual agonists and triple agonists

Another combination adds an amylin analogue rather than a GIP target: CagriSema and the amylin–GLP-1 combination. Its REDEFINE studies illustrate why a combination’s trial result belongs to the tested intervention and population.

The TGA distinguishes GLP-1 and dual GIP/GLP-1 medicines. The published retatrutide phase 2 trial identifies the three receptor targets. None is a “GLP-3 receptor”. More targets alone cannot establish greater benefit, fewer adverse effects or regulatory approval.

What evidence connects the mechanism to clinical outcomes?

Different studies answer different questions. In a 1998 randomised crossover experiment, 20 healthy men received native GLP-1 or placebo during meal testing. The researchers observed changes in fullness and food intake. That human physiology study helped establish an appetite effect; it was not a long-term obesity trial of a modern medicine.

A clinical-outcome claim needs evidence for the actual intervention, population, comparator, endpoint and follow-up. An appetite score, change in body weight, glucose measure and cardiovascular event are separate outcomes. A receptor assay cannot substitute for any of them. Our clinical-trial results guide explains how to check the study design, and the obesity trial tracker separates reported results from registry status.

Why does a natural hormone pathway still require safety evidence?

A medicine changes the strength, duration or pattern of signalling. The fact that a pathway exists naturally does not establish the safety of a particular drug, formulation or unverified product.

The TGA specifically highlights delayed gastric emptying and the associated aspiration risk during general anaesthesia or deep sedation. That warning illustrates why a beneficial mechanism can also create a clinically important risk. Product-specific warnings and current Australian safety information belong alongside efficacy claims; our GLP-1 safety guide follows those regulator records.

Common GLP-1 questions

Is GLP-1 a hormone or a drug?

GLP-1 itself is a hormone. In everyday discussion, “GLP-1s” often means medicines that activate its receptor. Check the named active ingredient before interpreting a claim.

Is GLP-1 the same as insulin?

No. GLP-1-related signalling can influence insulin release, but GLP-1 and insulin are distinct hormones. A receptor agonist is not an insulin replacement merely because it affects glucose regulation.

Is tirzepatide a GLP-1 medicine?

It has GLP-1 receptor activity and is more precisely described as a dual GIP/GLP-1 receptor agonist. That description keeps its second target visible.

Does this explain which medicines are approved in Australia?

Mechanism and approval are separate questions. Use the Australian TGA/PBS guide for dated product records, indications and subsidy decisions.

Follow the evidence: our oral GLP-1 approval and trial tracker keeps formulation-specific FDA records and published trial results separate. The amylin-versus-GLP-1 guide decodes CagriSema, cagrilintide, petrelintide and eloralintide without treating every obesity-drug target as the same pathway.

Primary and regulator sources

• Shigeto et al., 2015: GLP-1 and insulin secretion in mouse and human islets — primary mechanistic research.
• Flint et al., 1998: GLP-1, satiety and energy intake in humans — acute randomised crossover experiment.
• DailyMed: Ozempic prescribing information — semaglutide mechanism and pharmacology.
• FDA orforglipron review record and Foundayo prescribing information — molecular classification and finished product.
• Jastreboff et al., 2023: retatrutide phase 2 obesity trial — primary human trial and receptor classification.
• TGA class safety update, 3 June 2025 — Australian class terminology and gastric-emptying warning.